ERBB2 and gastric cancer: The ToGA (Trastuzumab for Gastric Cancer) trial reveals that HER2- positive patients experienced longer overall survival (OS) after treated with trastuzumab plus chemotherapy compared with HER2-positive patients treated with chemotherapy alone (Bang et al. 2010).